Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AKR1C3-activated Prodrug AST-3424

PreclinicalSmall molecule

SSWOG Cancer Research Network

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent T Acute Lymphoblastic LeukemiaActive, not recruiting

Recurrent T Acute Lymphoblastic LeukemiaPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q3 2028

PreclinicalActive, not recruiting

Recurrent T Acute Lymphoblastic Leukemia

NCT04315324

Clinical

Trials by Indication[1]

Recurrent T Acute Lymphoblastic Leukemia1 trial

A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)

Active, not recruiting·SSWOG Cancer Research Network·Preclinical·NCT04315324·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AKR1C3-activated Prodrug AST-3424. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AKR1C3-activated Prodrug AST-3424 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AKR1C3-activated Prodrug AST-3424. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SWOG Cancer Research Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSWOG Cancer Research Network

Related News